Mind Medicine (MindMed) Inc. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -40.9M
Net Income -42.7M

Balance Sheet Metrics

Total Assets 275.3M
Total Liabilities 52.5M
Shareholders Equity 222.8M
Debt to Equity 0.24

Cash Flow Metrics

Operating Cash Flow -19.7M
Free Cash Flow -29.4M

Revenue & Profitability Trend

Mind Medicine Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i65.3M52.1M36.2M34.8M18.6M
Selling, General & Administrative i38.6M41.7M30.2M59.1M14.4M
Other Operating Expenses i-----
Total Operating Expenses i103.9M93.9M66.3M93.9M33.0M
Operating Income i-103.9M-93.9M-66.3M-93.9M-33.0M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i11.6M----
Interest Expense i2.3M--359.0K164.0K
Other Non-Operating Income-14.0M-6.5M8.0M20.0K-743.0K
Pre-tax Income i-108.7M-95.7M-56.8M-94.2M-33.9M
Income Tax i--0-1.2M0
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-108.7M-95.7M-56.8M-93.0M-33.9M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-91.8M-84.2M-71.2M-91.2M-33.0M
EPS (Basic) i$-1.54$-2.44$-1.84$-3.45$-1.95
EPS (Diluted) i$-1.54$-2.44$-1.84$-3.45$-1.95
Basic Shares Outstanding i7046106739157420308574632737708217748039
Diluted Shares Outstanding i7046106739157420308574632737708217748039

Income Statement Trend

Mind Medicine Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i273.7M99.7M142.1M133.5M80.1M
Short-term Investments i-----
Accounts Receivable i-----
Inventory i-----
Other Current Assets7.9M4.2M3.9M3.7M1.4M
Total Current Assets i281.6M103.9M146.1M137.2M81.5M
Non-Current Assets
Property, Plant & Equipment i-----
Goodwill i39.8M40.4M43.5M46.7M0
Intangible Assets i-527.0K3.7M6.9M-
Long-term Investments-----
Other Non-Current Assets613.0K224.0K331.0K--
Total Non-Current Assets i20.5M20.7M23.9M26.8M0
Total Assets i302.2M124.5M170.0M164.0M81.5M
Liabilities
Current Liabilities
Accounts Payable i2.0M4.1M2.1M4.2M2.0M
Short-term Debt i--72.0K--
Current Portion of Long-term Debt-----
Other Current Liabilities24.0M16.5M9.9M--
Total Current Liabilities i38.8M32.2M17.9M10.4M3.0M
Non-Current Liabilities
Long-term Debt i21.9M14.1M---
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-32.0K1.2M1.9M-
Total Non-Current Liabilities i21.9M14.2M1.2M1.9M2.6M
Total Liabilities i60.7M46.4M19.1M12.3M5.7M
Equity
Common Stock i00000
Retained Earnings i-398.9M-290.2M-194.5M-137.7M-44.6M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i241.4M78.1M150.9M151.7M75.9M
Key Metrics
Total Debt i21.9M14.1M72.0K00
Working Capital i242.8M71.6M128.2M126.8M78.5M

Balance Sheet Composition

Mind Medicine Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-108.7M-95.7M-56.8M-93.0M-33.9M
Depreciation & Amortization i527.0K3.2M3.2M2.6M0
Stock-Based Compensation i16.9M15.5M13.7M42.7M7.4M
Working Capital Changes i-2.1M924.0K-3.3M125.0K544.0K
Operating Cash Flow i-94.3M-76.0M-43.2M-47.6M-26.0M
Investing Activities
Capital Expenditures i-----
Acquisitions i--0-297.0K0
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i--0-297.0K0
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i11.0M15.0M0--
Debt Repayment i-128.0K-844.0K0--
Financing Cash Flow i252.5M21.7M40.4M81.9M71.6M
Free Cash Flow i-79.1M-64.4M-50.1M-45.8M-23.6M
Net Change in Cash i158.1M-54.3M-2.8M34.0M45.6M

Cash Flow Trend

Mind Medicine Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.99
Forward P/E -6.61
Price to Book 3.70
PEG Ratio -6.61

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -59.11%
Return on Assets -30.55%

Financial Health

Current Ratio 4.98
Debt to Equity 22.22
Beta 2.97

Per Share Data

EPS (TTM) $-1.34
Book Value per Share $2.45
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mnmd701.5M-5.993.70-59.11%0.00%22.22
Vertex 101.6B28.195.9122.77%31.86%8.89
Regeneron 60.8B14.451.9915.34%31.37%9.04
Adaptive 2.0B-11.9110.88-57.60%-59.07%121.39
Arcutis 1.9B-14.6713.97-57.33%-35.40%79.27
Travere Therapeutics 1.9B-5.3059.95-705.73%-50.64%1,220.18

Financial data is updated regularly. All figures are in the company's reporting currency.